flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 GLP therapies have established themselves

Oral semaglutide, tirzepatide injections, and combination formulas are also available

This includes but is not limited to, conducting checkups and asking questions over the phone and video chat options, handling simple advisory medical tasks over virtual platforms, and even administering medical care via services that can meet you at home or direct you to nearby resources

In addition to problem-focused visits, we offer sports performance evaluations to stop problems before they start

Hims said its offering a treatment with the same active ingredient as Wegovy for $199 a month

The Journal of Clinical Investigation family of journals To view or add a comment, sign in Retatrutide (LY-3437943) is a next-generation triple incretin receptor agonist that simultaneously activates the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)

Cardiovascular Health: Semaglutide extends beyond blood sugar control, offering potential cardiovascular benefits and reducing associated risks